CAR-T therapies for multiple myeloma will be produced in the Technopolis Moscow SEZ

The production of unique drugs for blood cancer is being localized in the capital. A new biopharmaceutical manufacturing facility will be established within the Technopolis Moscow Special Economic Zone (SEZ). An agreement to this effect was signed at the 2nd Moscow Investment and Industrial Forum by Anatoly Garbuzov, a Moscow Government Minister and Head of the Department for Investment and Industrial Policy, and Irina Panarina, General Director of the pharmaceutical company AstraZeneca for Russia and Eurasia.

"Moscow is developing the pharmaceutical sector as a strategic industry for the city. The Technopolis Moscow SEZ is home to Russia’s largest cluster in this field, with 10 enterprises already operating there. They produce unique medications for treating oncological, autoimmune, cardiovascular, and other diseases. The company that signed the agreement today will become a new member of this cluster, localizing the full production cycle for CAR-T therapies—from the preparation of cellular material to the final drug product. The level of localization will reach approximately 90%," noted Anatoly Garbuzov.

CAR-T therapy is one of the most advanced and complex methods for treating cancer; it involves modifying a patient’s own immune cells so that they can recognize and destroy tumor cells.

The new high-tech facility will be highly automated. It will have the capacity to produce over 2,000 doses of these therapies annually—a tenfold increase over the current usage levels of CAR-T therapy in Russia. This scale will not only meet the needs of the Russian healthcare system but, in the future, will also allow for the supply of treatments to patients in EAEU member states. Over time, the site is also expected to expand into other cutting-edge areas, including TCR-T-based cancer immunotherapies.

"For us, this is a long-term project that extends well beyond the creation of a single manufacturing facility." "We are focusing on developing the infrastructure, technologies, and expertise required to ensure that advanced medicinal products can not only be used but also manufactured in Russia. Our strategic objective is to create conditions that provide Russian patients with faster and more sustainable access to innovative therapies," commented Irina Panarina.

The establishment of a production facility will be accompanied by the development of partnerships with Russian scientific, medical, and educational institutions. This collaboration will encompass the development and transfer of manufacturing processes, quality control, professional training, and the implementation of new technologies within the pharmaceutical sector.

Sergey Sobyanin has designated October 2026 as "Moscow Industry Month." The program includes over 25 events tailored for businesses, students, young professionals, city residents, and tourists. The capital is currently hosting the Moscow Investment and Industrial Forum. Additionally, the city is hosting the International Forum of Special Economic Zones for the first time, welcoming partners from BRICS, the EAEU, and the Shanghai Cooperation Organization.

The Moscow Investment and Industrial Forum serves as a platform for dialogue between representatives of municipal and federal authorities, investors, and industrial leaders. This is the second time the forum has been held in the capital, following its inaugural edition in 2025. Discussions at the forum cover investment policy, support measures for enterprises, technological development, and workforce training. The event is organized by the Moscow Government and the city’s Department of Investment and Industrial Policy.